Inhibitors of NO-synthases
The substances of the invention are highly effective low-molecular NO-synthases inhibitors. They can be synthesised easily and inexpensively in high purity via standard methods and exhibit selectivity for the bNOS present in the central nervous system which is involved in neuronal diseases as Alzheimer’s and Parkinson’s disease, multiple sclerosis and migraine. Thus, it is of particular importance that the inhibitors, after oral up-take and subsequent resorption via the intestinal epithelium, are able to cross the blood-brain barrier.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Successful experiment paves the way for new element
Scientists have found an alternative way to produce atoms of the superheavy element livermorium. The new method opens up the possibility of creating another element that could be the heaviest…
A new spectroscopy reveals water’s quantum secrets
For the first time, EPFL researchers have exclusively observed molecules participating in hydrogen bonds in liquid water, measuring electronic and nuclear quantum effects that were previously accessible only via theoretical…
A ‘new synthetic frontier’ for quantum dots
Replacing organic solvents with molten salt lets researchers grow “previously unimaginable nanocrystals”. The type of semiconductive nanocrystals known as quantum dots are both expanding the forefront of pure science and…